$ARTV

Artiva Biotherapeutics, Inc.

CIK:0001817241|SEC Filings

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating Expenses [Abstract]
Research and development (including related party amounts of $13, $27, $26, and $50, respectively)	$ 21,925	$ 17,861	$ 41,237	$ 34,914
General and administrative	4,965	4,949	10,083	10,068
Total operating expenses	26,890	22,810	51,320	44,982
Loss from operations	(26,890)	(22,810)	(51,320)	(44,982)
Other income, net:
Interest income	1,886	1,561	2,798	3,425
Other (expense) income, net	(1)	(5)	1	(8)
Total other income , net	1,885	1,556	2,799	3,417
Net loss	$ (25,005)	$ (21,254)	$ (48,521)	$ (41,565)
Net loss per share - basic	$ (0.63)	$ (0.87)	$ (1.51)	$ (1.71)
Net loss per share - diluted	$ (0.63)	$ (0.87)	$ (1.51)	$ (1.71)
Weighted average common shares outstanding - basic	39,413,236	24,378,823	32,086,532	24,360,502
Weighted average common shares outstanding - diluted	39,413,236	24,378,823	32,086,532	24,360,502
Net loss	$ (25,005)	$ (21,254)	$ (48,521)	$ (41,565)
Other comprehensive (loss) income:
Unrealized (loss) gain on investments, net	(3)	2	(124)	131
Comprehensive loss	$ (25,008)	$ (21,252)	$ (48,645)	$ (41,434)

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net loss	$ (48,521)	$ (41,565)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	1,358	1,269
Stock-based compensation	3,458	3,601
Accretion of discounts and amortization of premiums on investments, net	(315)	(1,232)
Changes in operating assets and liabilities:
Other receivables (including related party amounts of $61 and $(30), respectively)	(74)	116
Prepaid expenses and other current assets	1,850	(3,614)
Other long-term assets	(351)	229
Accounts payable (including related party amounts of $0 and $(271), respectively)	1,032	(168)
Accrued expenses (including related party amounts of $22 and $(715), respectively)	17	(1,481)
Operating lease right-of-use asset and lease liabilities, net	241	21
Net cash used in operating activities	(41,305)	(42,824)
Investing activities:
Purchases of property and equipment	(657)	(1,566)
Purchases of investments	(6,442)	(24,591)
Maturities of investments	40,000	57,250
Net cash provided by investing activities	32,901	31,093
Financing activities:
Proceeds from public offering of common stock and issuance of pre-funded warrants	300,000
Issuance costs paid in connection with public offering of common stock and issuance of pre-funded warrants	(16,793)
Proceeds from exercise of stock options	67	138
Proceeds from purchase of ESPP shares	138	134
Payments to taxing authorities related to net-settlement of vested restricted stock units	(210)	(39)
Payments on finance leases	(45)	(66)
Net cash provided by financing activities	283,157	167
Net increase (decrease) in cash, cash equivalents and restricted cash	274,753	(11,564)
Cash, cash equivalents and restricted cash at beginning of period	27,162	40,493
Cash, cash equivalents and restricted cash at end of period	301,915	28,929
Reconciliation of cash, cash equivalents and restricted cash to the balance sheet:
Cash and cash equivalents	301,454	28,468
Restricted cash	461	461
Total cash, cash equivalents and restricted cash	301,915	28,929
Supplemental disclosures of noncash activities:
Offering costs in accrued expenses	483
Property and equipment purchases in accounts payable and accrued expenses	$ 14	283
Right-of-use asset obtained in exchange for new operating lease liability		$ 442

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 301,454	$ 26,701
Short-term investments	47,940	81,307
Other receivables (including related party amounts of $0 and $61, respectively)	141	67
Prepaid expenses and other current assets	2,741	4,591
Total current assets	352,276	112,666
Restricted cash	461	461
Property and equipment, net	5,671	6,618
Operating lease right-of-use assets	9,236	10,525
Financing lease right-of-use asset	180	212
Other long-term assets	809	458
Total assets	368,633	130,940
Current liabilities:
Accounts payable	1,386	355
Accrued expenses (including related party amounts of $22 and $0, respectively)	9,896	9,600
Current portion of operating lease liabilities	3,299	3,015
Current portion of financing lease liability		44
Other current liabilities		73
Total current liabilities	14,581	13,087
Operating lease liabilities, net of current portion	6,550	7,883
Total liabilities	21,131	20,970
Commitments and contingencies (Note 10)
Stockholders' equity :
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; zero shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 700,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,792,279 and 24,595,550 shares issued and outstanding at June 30, 2026 and December 31, 2025 respectively	5	3
Additional paid-in capital	726,588	440,413
Accumulated other comprehensive (loss) income	(21)	103
Accumulated deficit	(379,070)	(330,549)
Total stockholders' equity	347,502	109,970
Total liabilities and stockholders' equity	$ 368,633	$ 130,940